SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-19-005326
Filing Date
2019-08-08
Accepted
2019-08-08 16:08:16
Documents
53
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q f10q_080819p.htm 10-Q 595117
2 EXHIBIT 10.1 exh_101.htm EX-10.1 132923
3 EXHIBIT 31.1 exh_311.htm EX-31.1 9275
4 EXHIBIT 31.2 exh_312.htm EX-31.2 9605
5 EXHIBIT 32.1 exh_321.htm EX-32.1 4204
6 EXHIBIT 32.2 exh_322.htm EX-32.2 4035
13 GRAPHIC exh101_header.jpg GRAPHIC 5415
14 GRAPHIC exh101_footer.jpg GRAPHIC 3233
  Complete submission text file 0001171843-19-005326.txt   4248387

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE bcrx-20190630.xml EX-101.INS 753935
8 XBRL SCHEMA FILE bcrx-20190630.xsd EX-101.SCH 49879
9 XBRL CALCULATION FILE bcrx-20190630_cal.xml EX-101.CAL 36929
10 XBRL DEFINITION FILE bcrx-20190630_def.xml EX-101.DEF 359771
11 XBRL LABEL FILE bcrx-20190630_lab.xml EX-101.LAB 336047
12 XBRL PRESENTATION FILE bcrx-20190630_pre.xml EX-101.PRE 371577
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 191009541
SIC: 2836 Biological Products, (No Diagnostic Substances)